Eli Lilly’s drug-induced depression
TWO months ago, when Eli Lilly announced promising results from its clinical trials with Zovant, a new drug for septic shock, its share price soared. Now, the Indianapolis-based drug firm could do with some new medicine to deal with a nasty shock of its own over Prozac, the antidepressant that is its most famous and lucrative product.
This article appeared in the Business section of the print edition under the headline “Eli Lilly’s drug-induced depression”
From the August 12th 2000 edition
Discover stories from this section and more in the list of contents
Explore the editionDiscover more
Could seaweed replace plastic packaging?
Companies are experimenting with new ways to reduce plastic waste
Has Sequoia Capital outgrown its business model?
Venture capital’s hardiest perennial gets back to its roots
On stupid rules and quick wins
Why every boss can benefit from asking employees what most infuriates them
TikTok wants Western consumers to shop like the Chinese
It still has some convincing to do
Will the trouble ever end for Volkswagen and its rivals?
From strikes to Trump tariffs, calamities abound
After Northvolt’s failure, who will make Europe’s EV batteries?
The continent looks ever more reliant on Asian producers